Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about KURA, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Ziftomenib FDA approved Nov 2025 · Komzifti |
Acute Myeloid Leukemia (AML) | Phase 3 · NCT07007312 | Recruiting |
| Daunorubicin | Acute Myeloid Leukemia (AML) | Phase 3 · NCT07007312 | Recruiting |
| Tipifarnib | HNSCC | Phase 1/2 · NCT04997902 | Completed |
| Pegaspargase | Lymphoblastic Leukemia | Phase 1/2 · NCT05848687 | Recruiting |
| Mezigdomide | KMT2A-rearranged | Phase 1 · NCT07355335 | Recruiting |
| Osimertinib | NSCLC | Phase 1 · NCT05693090 | Withdrawn |
| Darlifarnib | Solid Tumors With HRAS Alterations | Phase 1 · NCT06026410 | Recruiting |
| Gilteritinib | AML | Phase 1 · NCT06001788 | Recruiting |
| Fludarabine | AML | Phase 1 · NCT06001788 | Recruiting |
| Edaxeterkib (KO-947) | Advanced Malignant Neoplasm | Phase 1 · NCT03051035 | Terminated |
| Gemtuzumab | Acute Myeloid Leukemia | Phase 1 · NCT06448013 | Recruiting |
| Idarubicin | AML | Phase 1 · NCT06001788 | Recruiting |
Also used in these trials (approved or third-party drugs, not KURA's own candidates): Azacitidine, Venetoclax, Cytarabine, Hydroxyurea, Vorinostat, Mitoxantrone, Midazolam Hydrochloride, Methotrexate, Mercaptopurine, Itraconazole, Alpelisib, Blinatumomab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
KURA holds $492.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $58.5M/quarter from operations, an estimated runway of 25.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 20 · Moderate
We believe that our cash, cash equivalents and short-term investments as of September 30, 2026 will be sufficient to fund our current operating plan into 2028.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KURA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Montanova Capital, LLC | Institution (13G, 5%+) | 8,575,422 | 9.33% | 2026-06-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 7,908,832 | 8.61% | 2026-09-30 |
| BVF PARTNERS L P/IL | Institution (13G, 5%+) | 6,690,108 | 7.28% | 2026-09-30 |
| STATE STREET CORPORATION | Institution (13G, 5%+) | 4,931,090 | 5.37% | 2025-12-31 |
| Vanguard Capital Management | Institution (13G, 5%+) | 4,428,812 | 4.82% | 2026-03-31 |
| Troy Edward Wilson President and CEO, Director · +1.12M options |
Insider | 1,414,650 | 1.54% | 2026-11-13 |
| Teresa Brophy Bair Chief Legal Officer · +100,000 options |
Insider | 187,002 | 0.20% | 2026-09-28 |
| Thomas Malley Director · +35,000 options |
Insider | 149,557 | 0.16% | 2026-03-18 |
| Kathleen Ford Chief Operating Officer · +100,000 options |
Insider | 142,986 | 0.16% | 2026-09-28 |
| Thomas James Doyle SVP, Finance & Accounting · +42,500 options |
Insider | 142,928 | 0.16% | 2026-09-28 |
| Mollie Leoni Chief Medical Officer · +100,000 options |
Insider | 141,095 | 0.15% | 2026-09-28 |
| Brian T. Powl Chief Commercial Officer · +100,000 options |
Insider | 136,819 | 0.15% | 2026-09-28 |
Share count 91,878,694 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2025-11-30 | KOMZIFTI | NDA | +18.3% | -5.8% | -1.6% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KURA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →